Test gel with cisplatin injected into head and neck tumors
Part of Cancer clinical trials.
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 80 years old
- You have primary head and neck cancer (it may have spread to other areas)
- Your cancer is progressing or is resistant to radiation/standard treatments, and you can’t tolerate them
- You have a measurable tumor that can be seen/measured by ultrasound, MRI, or CT
- You can do study visits and understand/sign consent
- Your health tests are adequate (heart/overall status 0–2, and blood, kidney, and liver function not too low)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial compares two cisplatin dosing schedules (weekly low-dose vs higher dose less often) given alongside radiation for certain head and neck cancers. It’s testing which schedule works well while keeping side effects manageable during planned, curative-intent radiation.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests whether giving two rounds of cisplatin chemo along with radiation after surgery can help people with high-risk head and neck squamous cell carcinoma. It is for patients who have already had surgery and whose cancer showed signs of being more aggressive.
This study looks at immune system markers in patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. The goal is to understand how well a different chemotherapy drug (docetaxel) combined with radiation works in these patients.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.